Skip to main content
News Ulas 10.2019
During tumor development, macrophages (brown), the scavengers of the immune system, migrate into the diseased tissue (cancer cells: blue) without destroying it.
© Karin E. de Visser / the Netherlands Cancer Institute

Publication

New method identifies aggressive breast cancer

Aggressive forms of breast cancer often manipulate the immune response in their favor. This manipulation is revealed in humans by the same immunological "signature" as in mice. This is shown by a study carried out by scientists from the University of Bonn and memebers of the Cluster of Excellence ImmunoSensation together with Dutch colleagues. Their method makes it possible to obtain an indication of the prognosis of the disease using patients' tumor tissue. The results are published in the journal "Cell Reports".


Publication

Sander Tuit, Camilla Salvagno, Theodore S. Kapellos, Cheei-Sing Hau, Lea Seep, Marie Oestreich, Kathrin Klee, Karin E. de Visser, Thomas Ulas und Joachim L. Schultze: Transcriptional signature derived from murine tumor-associated macrophages correlates with poor outcome in breast cancer patients. Cell Reports; DOI: 10.1016/j.celrep.2019.09.067

Contact

Dr. Thomas Ulas

Head of the Bioinformatics Working Group

LIMES-Institute

University of Bonn

Tel. +49-228-7362722

E-mail: t.ulas@uni-bonn.de

Related news

Dr. Clivia Lisowski und Prof. Christian Kurts

Publication

Immune cells in the liver help pigeons navigate

—How do pigeons find their way home safely over distances of many kilometers? A research team from the University Hospital Bonn (UKB), the University of Bonn, the University of Duisburg-Essen, and the Max Planck Institute for Behavioral Biology has now discovered a previously unknown mechanism: specific immune cells in the liver may help the birds detect the Earth’s magnetic field. The findings have now been published in the journal Science.
View entry
News Icon

Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

—A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

Publication

Driver of inflammation after mild head injury

—Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry

Back to the news overview